`# CD314/NKG2D/KLRK1 Drug Discovery Landscape & Assay Solutions
Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD314 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD314 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD314 Products |
| Gene Delivery | CD314 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD314 Products |
| Benchmark Ab | Anti-CD314 (Sequence of NNC0142) Recombinant positive control. |
View CD314 Products |
| Validator | CD314 siRNA Set For knockdown verification. |
View CD314 Products |
| Related Target A | MICA Stress-induced ligand triggering NKG2D-mediated NK cell activation. |
View MICA Products |
| Related Target B | MICB Highly polymorphic ligand critical for tumor immune escape profiling. |
View MICB Products |
| Related Target C | DAP10 Essential signaling adaptor protein requiring co-expression for functional CD314 assembly. |
View DAP10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand-competition screening (MICA/B vs ULBPs) | Human/Mouse/Cyno ortholog proteins available with >95% purity, HEK293 expressed for native glycosylation. |
| Conformation-dependent cell activation assay | Lentiviral vectors for stable co-expression of CD314 and DAP10 in reporter cells. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD314 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD314 therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific NK cell engagers (NKCEs) and CAR-NK therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the preservation of NK cell fitness and overcoming shedding-induced immune evasion by tumor cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NK Cell Engagers (NKCE) | Innate Pharma, Sanofi | Hematological & Solid Tumors | Multivalent affinity tuning (Need high-purity monomeric and dimeric CD314) |
| CAR-NK / CAR-T | Celyad Oncology, Nkarta | AML, Solid Tumors | Ligand-binding domain verification (Need recombinant MICA/B targets) |
| Monoclonal Antibody (Antagonist) | Novo Nordisk | Celiac Disease, IBD | Ligand blocking assays (Need sequence-verified benchmark NNC0142) |
Title: CD314 (NKG2D) Market Landscape & Assay Reagents | TarMart Description: Buy high-purity CD314 antigens, biosimilar antibodies, and lentivirus. Analyze clinical trends (NKCE/CAR-NK) with our live tracker. Keywords: CD314 recombinant protein, NKG2D biosimilar, CD314 market forecast, KLRK1 drug discovery, NK cell engager assay.